The mammalian Hippo signaling pathway has been implicated in oncogenesis in the context of solid tumors such as hepatocellular carcinoma. MST1 kinase, the core component of the Hippo signaling pathway, is highly expressed in hematopoietic cells. However, its possible impact on tumorigenesis in this setting is unknown. In this study, we provide evidence that Mst1 loss in the mouse enhances chemically and genetically induced lymphoma development by inducing chromosomal instability. Mst1 deficiency increased susceptibility to T-cell acute lymphoblastic leukemia induced by mutagen exposure. Notably, before transformation Mst1 -/-normal thymocytes showed no changes in proliferation or apoptosis in vitro and in vivo, but they displayed elevated levels of abnormal mitotic chromosomes and aneuploidy, conditions known to promote tumorigenesis. Mst1 -/-mice also showed accelerated formation of spontaneous lymphomas in a p53 deficient background, accompanied by severe aneuploidy.
Introduction
Mst1 (also known as Stk4) is a serine/threonine kinase that belongs to the mammalian-Ste20-kinase family (1) . Most previous studies have focused on the apoptosis-related functions of Genetic screening studies in Drosophila have defined the Hippo signaling pathway, showing that this pathway is an important developmental program that controls proliferation and apoptosis for proper organ development (6, 7) . According to the current model, Hippo, the Drosophila homolog of Mst1/2, phosphorylates and thereby activates the Warts kinase (Lats1/2 in mammals) with the help of Salvador (Sav1 in mammals). Warts activity is further enhanced by binding to Mats (Mob1 in mammals), another substrate of Hippo. Activated Warts, in turn, phosphorylates and inactivates the transcriptional co-activator Yorkie (Yap1 in mammals) (8) . Importantly, Drosophila mutants for hippo, salvador, or warts show a severe overgrowth phenotype in mutant tissues. By extension, the mammalian Hippo pathway likely represents a new tumor-suppressor pathway (6, 7) .
Consistent with this assumption, genetically engineered mouse models of mammalian
Hippo pathway components frequently develop spontaneous tumors (9) (10) (11) (12) (13) (14) (15) (16) . Of note, liverspecific Mst1/2-or Sav1-knockout mice eventually develop liver cancers accompanied by Yap1 upregulation (12) (13) (14) (15) ; and Yap1-overexpressing transgenic mice show enlarged livers and ultimately succumb to liver cancer (16) . These observations clearly demonstrate that the mammalian Hippo pathway has a crucial role in preventing tumorigenesis though inactivation of Yap1. However, whether Mst1 has tumor-suppressive functions in organs other than the Author Manuscript Published OnlineFirst on August 27, 2012; DOI: 10.1158/0008-5472. liver and intestine, and whether Mst1 can function as a tumor suppressor independently of the canonical Hippo signaling pathway (i.e., inactivation of Yap1) remains to be answered.
Chromosomal instability is a phenomenon in which whole chromosomes are missegregated during mitosis. Chromosomal instability, as well as its consequence, aneuploidy, are common characteristics of most cancers (17) and correlate with poor prognosis in some types of cancers (18) . Many studies have provided evidence that chromosomal instability participates in tumor initiation and progression (19) . In fact, a series of genetic studies in mice with defects in the spindle assembly checkpoint suggested that aneuploidy or chromosomal instability promotes the development of tumors (20) (21) (22) (23) (24) . Interestingly, MST1
and MST2 have been shown to be crucial for precise alignment of mitotic chromosomes.
HeLa cells depleted of MST1, MST2, or its downstream kinase NDR1, show unaligned metaphase chromosomes, which can potentially lead to aneuploidy (25, 26) . Intriguingly, Ndr1-knockout mice developed T-cell lymphomas at their old age (27) .
Here, for the first time, we demonstrate that Mst1 functions in suppressing tumor development in lymphocytes in vivo. Lymphoma development is accelerated in Mst1-deficient mice upon mutagen treatment or p53 deletion. Furthermore, Mst1-deficient lymphocytes are prone to mis-segregate chromosomes during mitosis and show increased levels of aneuploidy, which likely contributes to tumorigenesis. These data suggest that Mst1 functions as a tumor suppressor in lymphocytes by maintaining genomic integrity during mitosis.
Materials and Methods

Mice
Mst1
-/-mice (28) were backcrossed to C57BL/6 mice seven times before being used in 
Flow cytometry
For double-negative (DN) subset analysis, thymocytes were stained with antibodies against the following lineage-specific markers: CD4 (RM4-5), CD8a (53-6.7), TCRβ (H57-597), Gr1
(PC61.5), and c-Kit (2B8). All antibodies were purchased from BD Biosciences or eBioscience. Flow cytometric analyses were performed using a FACS Calibur or LSR II (BD Biosciences) system.
Cell proliferation
For in vitro proliferation assays, thymocytes were placed in 96-well plate with RPMI-1640 medium at a density of 2x10 5 (BD Biosciences) according to the manufacturer's instructions.
Histological analyses
Tissues were fixed in 10% formalin at 4 °C, embedded in paraffin, sectioned (4 μm thickness), and stained with hematoxylin and eosin (H&E).
Immunofluorescence
Freshly isolated thymocytes were incubated with RPMI-1640 medium supplemented with 5 ng/ml PMA and 250 ng/ml ionomycin for 60 hours. Cytospin preparations of cultured thymocytes were fixed, permeabilized, and stained with antibodies against phosphorylated histone H3 (Cell Signaling) and α-tubulin (Calbiochem), and then counterstained with 4',6-diamidino-2-phenylindole (DAPI). Confocal images were obtained using a LSM710 laserscanning confocal microscope (Carl Zeiss).
Metaphase chromosome spreads
Freshly isolated splenocytes were incubated with RPMI-1640 medium containing 5 μg/ml lipopolysaccharide (Sigma) and 5 μg/ml concanavalin A (Sigma) for 48 hours before used in karyotyping. Karyotyping procedures were described previously (21) .
Array comparative genomic hybridization (array CGH)
Array CGH studies were performed using the SurePrint G3 mouse CGH Microarray 180k Kit Materials and Methods for details.
Results
Mst1 deficiency increases susceptibility to ENU-induced lymphomagenesis.
Mst1 is most abundantly expressed in hematopoietic cells, including lymphocytes, and plays a role in regulating peripheral T cell proliferation and adhesion (31, 32) . However, Mst1 -/-mice rarely develop spontaneous tumors in lymphoid organs (15) . To investigate whether Mst1 plays a role in inhibiting mutagen-induced tumorigenesis in lymphocytes of these mice, we injected wild-type and Mst1
-/-mice with the same amount of ENU, which is a highly potent mutagen that induces mostly thymic lymphomas in mice (33) . During the 8-month observation, only 5% of wild-type mice died at this dose of ENU, whereas 50% of Mst1 Table S1 ). In most cases, the thymus and spleen were massively enlarged in these moribund 
Mst1 is not required for T-lineage development.
To elucidate the mechanism by which Mst1 deficiency accelerates T lymphoma development, at certain stages, such as DN3 or DP, has been reported to accelerate lymphoma development in several mouse models (34, 35) . Mst1 -/-mice showed no significant differences in thymocyte composition except for a mild increase in SP cells, as previously reported ( Fig. 2A,   B ). Increases in CD4 and CD8 SP subsets are thought to be due to a defect in thymic egress (31, 36) . A more detailed analysis of DN populations also revealed normal development through DN1 to DN4 stages in these mutant animals (Fig. 2C, D) . Furthermore, BrdU pulsechase experiments revealed that Mst1 -/-thymocytes that incorporated BrdU during their DN stages progressed to DP (day 2) and SP (day 5) cells with similar kinetics to wild-type cells (Supplementary Fig. S2A-B) . Thus, these data suggest that Mst1 deficiency does not induce overt defects in thymocyte development that might contribute to lymphomagenesis.
Mst1 deficiency does not significantly affect thymocyte proliferation or apoptosis.
Given that Mst1 mediates crucial apoptotic functions, we investigated whether Mst1 deficiency affected basal apoptotic levels in thymocytes. However, annexin-V staining revealed no significant reduction in the apoptotic levels of Mst1 -/-thymocytes compared to wild-type thymocytes both in freshly isolated and in vitro cultured conditions (Fig. 3A, Research. than in wild-type cells (Fig. 4A-E, Supplementary Fig. S3 ). The percentage of cells having misaligned metaphase chromosomes, lagging chromosomes, or chromosome bridges was all increased in Mst1 -/-cells compared to wild-type cells (Fig. 4B-D) . Furthermore, micronuclei were more frequently observed in Mst1 -/-cells after cytokinesis (Fig. 4Am-p) .
Next, we investigated whether the observed chromosomal instability in Mst1 -/-cells could contribute to the formation of aneuploidy in primary lymphocytes. Chromosome spreads from wild-type and Mst1 -/-splenocytes showed that the latter contained a higher percentage of aneuploid cells whose chromosome numbers deviated from the normal modal number of 40 ( Fig. 4F-H) . These results indicate that Mst1 -/-lymphocytes showed increased levels of chromosomal instability, which might contribute to accelerated lymphoma formation in ENU-treated Mst1 -/-mice.
Loss of Mst1 accelerates lymphoma development in p53 -/-mice.
The p53 pathway has recently been shown to inhibit proliferation of aneuploid cells in culture (17) and suppress tumor development in aneuploidy-generating mouse models (37).
These facts led us to hypothesize that aneuploid cells induced by the loss of Mst1 would be able to proliferate and contribute to lymphomagenesis in the absence of functional p53. To test this hypothesis in vivo, we examined tumor-free survivals of p53 -/-Mst1 +/+ and p53 -/-Mst1 -/-mice. As reported in previous study (29), all p53 -/-Mst1 +/+ mice developed tumors within 8 months of age (Fig. 5A) . The tumors that developed in these mice included thymic lymphoma (50%), sarcoma (25%), and one brain tumor (Supplementary Table S2 (Fig. 5C ).
To further investigate the effects of Mst1 deficiency on chromosomal instability, we
Research. (Fig. 5D ). However, we could not observe more gross abnormalities in p53 
Lymphoma acceleration by Mst1-deficient mice is not dependent on Yap1 activation.
Given that the inactivation of Yap1 by Mst1/2 signaling is a key mechanism for tumor suppression in the liver (38), we sought to examine whether accelerated lymphoma development in Mst1-deficient mice is caused by activation of Yap1. To test this, we examined Yap1 expression according to Mst1 genotypes. Importantly, Yap1 expression in lymphoid tissues (thymus, spleen, and lymph node) from wild-type mice was below the limit of detection by ordinary immunoblotting, whereas large amounts of Yap1 were expressed in most epithelial tissues (lung, liver, and pancreas) ( Supplementary Fig. S4A ). Yap1 was also barely detectable in lymphoid tissues from Mst1 -/-mice (data not shown). Although Yap1 is not expressed in normal lymphoid tissues, it is possible that Yap1 is specifically upregulated Fig. S4B ). Specifically, only two out of seven lymphoma samples showed mild Yap1 expression. These data suggest that Yap1 upregulation is not critical for ENU-induced lymphoma development in Mst1 -/-mice.
Unlike ENU-induced lymphoma cells, spontaneous lymphomas from p53-null background mice usually exhibit Yap1 upregulation, as determined by immunoblotting and RT-PCR ( Supplementary Fig. S4C, D Ser127 phosphorylation, at least not in p53 -/-Mst1 +/+ lymphoma cells.
MST1 (STK4) expression is reduced in various human lymphoma/leukemia samples.
Finally, we sought to determine whether our genetic studies in mice have clinical relevance to human hematopoietic malignancies. We thus performed in silico screening of the microarray database at the Oncomine website to examine expression levels of MST1 (STK4) in human hematopoietic malignancies. The human disease that most closely corresponds to our mouse lymphoma models is T-ALL, since both originate from immature precursor cells, involve upregulated Notch1, and are spread throughout the body (Fig. 1, 5 , Supplementary Fig. S1D -E) (39) . Hence, we examined acute lymphoblastic leukemia (ALL) samples for MST1
expression. The median expression values of MST1 in both T-ALL and B-ALL samples were significantly reduced compared to normal in two independent analyses (Fig. 6A, B) (40, 41) .
Similarly, remarkable down-regulation of MST1 was further confirmed in an independent cohort consisting of 117 T-ALL tissues (Fig. 6C) (42) .
Research. We then examined MST1 expression in lymphomas, which are believed to originate from more mature lymphocytes. The expression of MST1 was reduced in multiple mature B-cell lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma (Fig. 6D) (43) (44) (45) . These results suggest that MST1 insufficiency is likely an important contributing factor in the pathogenesis of precursor lymphoblastic leukemia as well as mature lymphocyte neoplasms in humans.
Discussion
Here, using two well-known mouse lymphoma models-ENU-induced lymphoma and p53 knockout-driven lymphoma-we report for the first time that loss of Mst1 accelerates tumor development. Although Mst1 deficiency accelerated tumor development in both settings, it had little, if any, effect on thymocyte proliferation or apoptosis. Instead, the accelerated tumorigenesis was accompanied by increased levels of chromosomal instability and aneuploidy in Mst1 -/-lymphocytes.
The rate of spontaneous apoptosis in Mst1 -/-thymocytes was comparable to that in wildtype thymocytes. Furthermore, in vitro culture with various apoptosis-inducing drugs revealed no differences in the rate of cell death between wild-type and Mst1 -/-thymocytes.
These results were quite surprising given the demonstrated pro-apoptotic role of Mst1 in many in vitro settings. Since we could not detect any increase of Mst2 expression in Mst1 
Both ENU-induced lymphoma and p53 knockout-driven lymphoma developed after long latencies (>4 months) and were clonal in origin. These characteristics suggest a requirement for additional genetic mutations in tumor development. In such circumstances, gain of a single genetic mutation that can impair the integrity of genome may accelerate tumor development by increasing the probability of acquiring additional mutations. In line with this argument, we found strong evidence that loss of Mst1 could trigger genomic instability in (26) . It is also noted that Ndr1-null mice were prone to the development of T-cell lymphoma at their old age (27 (38) . Liver-specific Mst1/2 homozygous mutant mice showed marked liver enlargement due to increased proliferation of hepatocytes, and eventually developed liver tumors. Thus, Mst1 and Mst2 satisfy the prerequisites of being gatekeepers in that both directly control cellular proliferation (46) . Here, we showed that, unlike the case of the liver, neither cell proliferation nor apoptosis in thymocytes was affected by the loss of Mst1. Instead, our study implies that Mst1 may serve as a "caretaker" (46) human lymphomas/leukemias. The expression levels of MST1 were significantly reduced in various lymphoma/leukemia patient samples, supporting our notion that the loss of MST1 could contribute to tumorigenesis in hematopoietic lineages. Our results from three independent T-ALL cohorts analyzed in this study showed different degree of MST1 downregulation (Fig. 6A left, dramatic; Fig. 6A right, subtle) . This discrepancy may have arisen because the diversity within T-ALLs, which can be classified into at least five subgroups with distinct gene expression pattern (49), was not taken into account.
In conclusion, our study has provided insights into the role of Mst1 in maintaining faithful segregation of chromosomes during mitosis in lymphocytes, and shown that deregulation of Mst1 accelerates lymphoma development in cooperation with p53 deficiency. A. Tumor-free survival curves for ENU-treated wild-type (n=24) and Mst1 -/-(n=26) mice. B. 
